SGD Pharma, a producer of moulded and tubular glass for pharmaceutical primary packaging, has signed an agreement with Italian private equity firm Entangled Capital to acquire Alphial S.r.l., a manufacturer of tubular vials and ampoules based in Italy. Alphial employs more than 220 people across four manufacturing sites. The transaction is subject to Italian foreign direct investment clearance.
The acquisition is intended to strengthen SGD Pharma’s tubular glass manufacturing capabilities and expand its presence in Europe. The company stated that the integration process will begin after closing.
Alphial produces ampoules, vials and ready-to-use (RTU) products. “We are excited to welcome Alphial S.r.l. to the SGD Pharma family. This acquisition represents a significant milestone in our growth strategy and will enable us to better serve our clients with an expanded portfolio of services and solutions,” said Olivier Rousseau, CEO of SGD Pharma.
“We have been investing heavily in the development of tubular glass and RTU over the last years. Together with the SGD Pharma team, I’m truly excited to engage with the Alphial team to make this happen,” said Fabio Invernizzi, General Manager of the West Business Unit. “We are really pleased to join the SGD Pharma Group. SGD Pharma will help Alphial grow and improve the quality of its offering and of its industrial performance,” added Valerio Marchi, CEO of Alphial S.r.l.
The company also highlighted its recent joint venture with Corning to establish a tubing facility near its Vemula plant in India, which is expected to begin production soon. SGD Pharma noted that the new Indian site aims to secure supply chains and reduce environmental impact.
SGD Pharma produces moulded and tubular glass for pharmaceutical primary packaging. The company operates five ISO 15378 certified and GMP compliant manufacturing plants and works with more than 90 agents and distributors worldwide. It supplies packaging for parenteral, oral, and nasal pharmaceutical products.
